- Home
- BANR vs ARQT Comparison
BANR vs ARQT Comparison
Compare BANR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANR
- ARQT
- Stock Information
- Founded
- BANR 1890
- ARQT 2016
- Country
- BANR United States
- ARQT United States
- Employees
- BANR N/A
- ARQT N/A
- Industry
- BANR Major Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BANR Finance
- ARQT Health Care
- Exchange
- BANR Nasdaq
- ARQT Nasdaq
- Market Cap
- BANR 2.1B
- ARQT 1.7B
- IPO Year
- BANR 1995
- ARQT 2020
- Fundamental
- Price
- BANR $64.90
- ARQT $14.74
- Analyst Decision
- BANR Buy
- ARQT Strong Buy
- Analyst Count
- BANR 5
- ARQT 7
- Target Price
- BANR $70.75
- ARQT $19.00
- AVG Volume (30 Days)
- BANR 242.4K
- ARQT 1.6M
- Earning Date
- BANR 07-16-2025
- ARQT 08-06-2025
- Dividend Yield
- BANR 2.99%
- ARQT N/A
- EPS Growth
- BANR 9.13
- ARQT N/A
- EPS
- BANR 5.25
- ARQT N/A
- Revenue
- BANR $624,024,000.00
- ARQT $263,464,999.00
- Revenue This Year
- BANR $0.95
- ARQT $61.83
- Revenue Next Year
- BANR $6.48
- ARQT $36.55
- P/E Ratio
- BANR $12.22
- ARQT N/A
- Revenue Growth
- BANR 5.10
- ARQT 99.50
- 52 Week Low
- BANR $52.86
- ARQT $8.03
- 52 Week High
- BANR $78.05
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- BANR 53.79
- ARQT 51.08
- Support Level
- BANR $61.88
- ARQT $13.70
- Resistance Level
- BANR $63.78
- ARQT $16.39
- Average True Range (ATR)
- BANR 1.52
- ARQT 0.82
- MACD
- BANR -0.04
- ARQT -0.06
- Stochastic Oscillator
- BANR 84.84
- ARQT 38.78
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.